GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Debt-to-Asset

Hansoh Pharmaceutical Group Co (HKSE:03692) Debt-to-Asset : 0.13 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co Debt-to-Asset?

Hansoh Pharmaceutical Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$4,593 Mil. Hansoh Pharmaceutical Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$114 Mil. Hansoh Pharmaceutical Group Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was HK$36,137 Mil. Hansoh Pharmaceutical Group Co's debt to asset for the quarter that ended in Dec. 2023 was 0.13.

Hansoh Pharmaceutical Group Co Debt-to-Asset Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co Debt-to-Asset Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial - - 0.14 0.15 0.13

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.14 0.15 0.14 0.13

Competitive Comparison of Hansoh Pharmaceutical Group Co's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hansoh Pharmaceutical Group Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's Debt-to-Asset falls into.


Hansoh Pharmaceutical Group Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Hansoh Pharmaceutical Group Co's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4593.089 + 114.245) / 36137.447
=0.13

Hansoh Pharmaceutical Group Co's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4593.089 + 114.245) / 36137.447
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co  (HKSE:03692) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Hansoh Pharmaceutical Group Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » Debt-to-Asset
Comparable Companies
HKSE:00867 HKSE:03320 HKSE:00570 HKSE:02096 HKSE:00512 HKSE:03933 HKSE:06185 HKSE:02005 HKSE:03613 HKSE:01349 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ NSE:DIVISLAB
Traded in Other Exchanges
3KY:Germany
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Website
https://www.hspharm.com
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.
Executives
Cen Junda 2307 Founder of a discretionary trust who can infl
Cantrust (far East) Limited 2301 Trustee
Jqc Holding Limited 2201 Interest of corporation controlled by you
Jqc International Limited 2201 Interest of corporation controlled by you
Sun Yuan 2101 Beneficial owner
Harmonia Holding Investing (ptc) Limited 2201 Interest of corporation controlled by you
Stellar Infinity Company Ltd. 2101 Beneficial owner
Sunrise Investment Advisors Limited 2201 Interest of corporation controlled by you
Zhong Huijuan 2307 Founder of a discretionary trust who can infl
Apex Medical Company Ltd. 2101 Beneficial owner

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines